Latest News (Test)

Obituary Linda Cooke

Linda Cooke
30th October 1950 – 21st January 2016
Our dear Linda Cooke sadly passed away peacefully with her son Andrew, daughter Helen and her best friend Bev by her side on Thursday 21st January 2016.There are special people in our lives who never leave us even after they are gone, Linda is without doubt one of those special people who will always be forever in our hearts, we will miss you.


Here is Linda’s Story……….


Linda was Trustee of the Alpha-1 UK Support Group and was always there, in person, on the end of the phone, by email and Facebook, to offer support and friendship to all who came within her sphere, no matter what walk of life they were from and no matter how ill, she herself was feeling…. 

Linda was always one of the first to welcome new members, who often had just been diagnosed, and had found the Alpha-1 UK Support Group whilst researching Alpha 1 on the internet. She would offer words of comfort, support and encouragement and somehow she always knew what to say to alleviate their fears of this little known illness.  When a member was listed for a transplant, she would offer them love and support, and when they were lucky enough to get “the call” she was there to support their family through this difficult time.

But it wasn’t just within the Alpha 1 community that she was like this.  To all her family and friends, she was a tower of strength, always there for them. Your problem was her problem, she would laugh with you, cry with you, celebrate your successes and give support in times of need.

But for all this the centre of her world was her son and daughter, Andrew and Helen.  Her world revolved around them and I know that she was happy in the knowledge that when the time came for her to leave this life, they would have Louise and Michael there to support them as well as family and friends.

Linda’s transplant gave her six extra years, sadly 3 of them with chronic rejection.  Nevertheless, she maintained a strong constitution and was always thankful of a second chance of life and wouldn’t have changed a thing.

She was so very much more than these words that I have taken from emails that she sent to the Alpha-1 UK Support Group in May 2014.  The first one is from a welcoming email she sent to a new member of the group, a brief outline of her Alpha journey, the second one is her celebrating her transplant birthday or tranniversary as the Alpha 1 community call it, remembering the day she got “the call”.  And although she was in chronic rejection, she still remained optimistic with no regrets.

3/5/2014  –  My name is Linda I am 63 years of age and was
diagnosed a
ZZ Alpha when I was 40 after years of being what Doctors called “chesty” and winters upon winters of bronchitis . I was wrongly
diagnosed as asthmatic.
I had a company medical when I was 40 and emphysema was picked up, further investigations showed I had Alpha 1 antitrypsin enzyme deficiency…”

What is alpha-1-antitrypsin? Alpha-1-antitrypsin (AAT) is a protein mainly produced by your liver that is released into in your blood. There are other proteins called enzymes that are found in all parts of your body that help to make sure that chemical reactions in your body take place normally. Enzymes have many important roles in your lung, including removing bacteria and fighting infections. The AAT protein is needed to control enzyme activity to prevent healthy lung tissue being damaged.

What is severe alpha-1-antitrypsin deficiency?  AATD is a rare, inherited condition that affects around one in 3,000 to one in 4,000 people in the UK. The most common reason for severe deficiency is if you carry an abnormal gene known as Z-AT, which affects the level of your AAT
protein.

To inherit AATD, a Z-AT gene must be passed on by both of your parents. If you carry two Z-AT genes, your AAT level will be only 10-20 per cent of what it should be.  The AAT protein
affected by the Z-AT gene builds up in the liver. This means you don’t have enough AAT to control the enzymes in your body, so healthy lung tissue can be damaged. This can cause emphysema, especially if you smoke.  Emphysema is one of the lung conditions known as
chronic obstructive pulmonary disease (COPD).

“Unbeknown to me at the time I had married an
MZ
man ( who
carried one bad gene ) and we had two children,a son
Andrew who is MZ like his Dad ,and a daughter  Helen who is ZZ like me…….my Mum and Dad were tested as MZ as were my two brothers.I was very fortunate to receive a double lung transplant in May 2009 at Papworth hospital in Cambridge, in fact it was 5 years ago tomorrow…my gratitude to my wonderful donor and her family is never ending ….sadly I have chronic rejection now but I’ve had that for the last two years so you can see I’m hanging on in.
My lung function at the time of transplant was 19% and I was very poorly …so I’ve been given another 5 years of life I wouldn’t have had. The criteria for a transplant then was to be 23% or below …that may have changed since then …..certainly the cut-off age has changed since I had my transplant ..it used to be 60 but they do them on older patients than that now.We have had members who have had transplants
last much longer than mine ….in fact at last
year’s annual meeting we met a member who was 21 years post-transplant…isn’t that amazing ? ….and when I go to my check-ups at Papworth I meet many others who are 10 , 15 and more years post-transplant…I was just very unlucky.
You’ll see we don’t always just talk of our health …. we may have lost many things but fortunately we haven’t lost our sense of humour.

I have been a member of this group since 2000 and I’m now a committee member and trustee, I have learnt so much valuable information since I joined and made so many wonderful friends…I hope
you do too.

04/05/2014  Morning all….special day for me today as it is
my 5 year anniversary of my double lung transplant…it only seems like
yesterday…….

It was a bank holiday weekend just like it is now…my mum had been over for Sunday lunch as usual and I had been showing her my case for Papworth with my new pj’s and all the things I needed for after the
op.
It had only been 9 days since I was listed and I had spent that time preparing things at home…getting my affairs in order and moving money into separate bank accounts to cover bills should I be away from home…cleaning the house, bringing all my washing and ironing up to date…I remember John Doyle said to me that I was like a creature nesting …..I finally finished doing all that on the Saturday and I sent a prayer up to God and said to him ” if ever there was a good time for my transplant now was it I was never gonna be more ready ” ..and he
answered because the next day Ann Thompson, my transplant coordinator, rang me around 5.30 in the afternoon…Mum and I had been watching the musical “Oliver ” Ann asked me if I was well and I replied “I was ” ….she then said “they may have something for me ” she asked me when I had last eaten and drunk anything and not to drink or eat anything from then on.

Everything went into action…I called the kids …neither were ready….I called my neighbours who had always agreed to be my transplant buddies at home …( I had always thought the call would come in the middle of the night ) they came over and Geoff took my Mum home for me…Penny ran around upstairs closing all the windows and switching things off…Helen arrived with her father in law…all were in a state of anxiety and panic, but not me ….I was so calm…where that came from I don’t know but there was a bubble of excitement running through me ..the song “something’s coming ” from West side story had been in my head for the past 9 days and it was in my head that day too …” who knows , could be , something’s coming something good , ..if I can wait”
By the time the car from Papworth came to get me, most of my neighbours had heard the news and were standing on their doorsteps waving me off and wishing me well…Helen and I got in the car (we were meeting Andrew at Papworth, as he was working at his Dads in
Surrey that day)
As we turned the corner of my road the driver put the blue light on and the siren went off.

Helen and I looked at each other in amazement, at what had happened in the last half hour…the rest is history …..My thoughts, of course, are always with my Donor…I thank her every day for her precious gift and my thoughts are with the family today, as they remember the sad day they lost her, but I remain eternally grateful to them…

Linda is now at peace, up there in Heaven, in the loving arms of her Mum and Dad, and chattering away ten to the dozen with Jane Hill, Chris Torrance John Doyle and all the Alphas that have been taken too soon.

R.I.P. Linda Cooke ….You can now breathe easy

30th October 1950 – 21st January 2016

Linda’s Funeral is Thursday 18th February at 12.45 at:

Easthampstead Park Cemetery and Crematorium
South Road
Bracknell
Wokingham
Berkshire
RG40 3DW

Afterwards at:

Easthampstead Park
Off Peacock Lane
Wokingham
West Berkshire
RG40 3DF

Linda’s family have requested that instead of flowers they would like a donation to Alpha-1 UK Support Group using the folling JustGiving page:

https://www.justgiving.com/Linda-susan-cooke

Published: 03/02/2016

An Open Letter to the Alpha-1 Community

This open letter is intended to give an update on the recent activities of the Alpha-1 UK Support Group on behalf of the Alpha-1 community in the UK, and to express the strong support of Alpha-1 Global and the Alpha-1 Foundation for those activities.


The Alpha-1 community in the UK is understandably excited about the 2015 publication of a paper on the RAPID trial, which involved the Alpha-1 (AAT) augmentation therapy Respreeza®, in the prestigious medical journal The Lancet, and the European Medicines Agency’s recent approval of Respreeza® for prescription use in Europe.

The National Institute for Health and Care Excellence (NICE) is currently considering a technology appraisal of Respreeza® to develop recommendations on its use in England. The scope of this potential health technology appraisal (HTA) has been under consultation with different stakeholder groups in the UK.

The Alpha-1 UK Support Group has formally responded in detail to the NICE draft scope consultation, and the charity’s Trustees Karen North and Dr Sandra Nestler-Parr attended the NICE scoping meeting on 16th October 2015.  The aim of the meeting was to discuss with all stakeholders – clinicians, patients, industry, the National Health Service (NHS), etc. – the most appropriate scop
e for a potential HTA for Respreeza®.

NICE is fully aware of all relevant evidence necessary to make a well-informed recommendation to Ministers on the most suitable HTA route.  Ministers will decide by February 2016 whether and how Respreeza® should be appraised by NICE.  The actual appraisal process will not commence until spring 2016 at the earliest.  All relevant information and status updates are available on the NICE website.

All signers of this letter are grateful to NICE for its consideration of the detailed response made by the Alpha-1 UK Support Group to NICE’s review of a potential HTA for Respreeza®.

Alphas have made enormous progress in the last few years in the UK.  Most recently, two Specialist NHS AATD Services have been established at the University Hospitals Coventry and Warwickshire and at the University Hospital Birmingham, offering multi-disciplinary, expert care for Alphas from across England.

The Alpha-1 UK Support Group has been able to drive these improvements in the care of Alphas only by building relationships with different stakeholders and engaging in the formal processes that are put in place by the government and the NHS.

At the same time, the charity continues to focus on its mission to support Alphas across the UK by providing education, advice, financial support, equipment hire and a platform for Alphas to connect with each other and share experiences.

The Alpha-1 UK Support Group’s trustees, and all volunteers, take their responsibility very seriously to work solely in the best interest of the charity’s membership and the wider Alpha-1 community.  They work beyond the call of duty to improve access to optimal care and treatment to enhance the quality of life of Alphas.

The Alpha-1 UK Support Group regularly reviews and updates its website, leaflets and brochures, and continues to make those materials available while review or updating is taking place, as a helpful resource to its membership and the wider community.

Fellow participants in Alpha-1 Global have frequently praised the Alpha-1 UK Support Group for its open and energetic collaboration to expand patient choices and improve access to care for Alphas in the UK and around the globe.

Alpha-1 Global and the Alpha-1 Foundation in particular laud the Alpha-1 UK Support Group for ably representing the patient point of view as NICE considers the scope of an HTA for Respreeza®, and we wholeheartedly support the charity’s strategy in actively participating in this essential process.

Alpha-1 Global

Alpha-1 Foundation

Alpha-1 UK Support Group

Published: 29/10/2015

Important Message from our Trustees

Dear Alpha-1 Patients,

We have repeatedly noticed that there still appears to exist confusion about the status of ADAPT and the available options for Alphas to receive specialist care in the NHS. We would like to clarify the situation.

ADAPT has always been a largely industry-funded research programme with no formal links to the NHS. There is no NHS process which allows the “transfer” of patients from a research programme, eg. ADAPT, to an NHS service, eg. specialist Alpha-1 clinics.

It is important to understand that every patient who has been attending ADAPT or any other research programme is free to choose where they want to attend specialist Alpha-1 NHS clinics – an automatic ‘transfer’ to a particular NHS service by a local doctor without prior discussion with the patient about their preferred choice is not appropriate.

You and your local doctor should be aware of the available choice that now exists in the NHS for Alpha-1 patients:  specialist multidisciplinary NHS clinics are operational, for example, at Addenbrooke’s Hospital in Cambridge, at the Royal Free Hospital in London and, as part of the new West Midlands Specialist NHS Alpha-1 Service, at the University Hospital in Coventry and at the University Hospital in Birmingham. All these centres have the necessary expertise and experience to provide optimal care for Alphas.

Please read the front page article of our latest Newsletter for detailed information about the differences between attending research programmes and NHS clinics, and about some (but not all) of the available specialist NHS Alpha-1 clinics in England and how to get referred there (include link to the newsletter).

It is important that you are fully aware of the available options in order to make an informed choice about your care!

If you have any further questions, please feel free to contact us via Facebook the Yahoo Group or info@alpha1.org.uk

Board of Trustees

Alpha-1 UK Support Group

Published: 27/09/2015

West Midlands Specialist NHS Alpha-1 Service Now Operational at Two Centres

Further to our announcement in April of the establishment of a multidisciplinary specialist NHS clinics for Alpha-1 patients in the West Midlands, we are pleased to announce that this service is now offered at two centres: Alpha-1 clinics at University Hospital Coventry are run by Dr David Parr and have been operational since May and, as of this week, Dr Alice Turner runs Alpha-1 clinics at the University Hospital Birmingham.

Both clinics are available to patients from across England, and patients can get referred to the clinic of their choice by their GP or local specialist.

The following links provide information and details of how to get referred and make an appointment:

University Hospitals Coventry and Warwickshire
www.uhcw.nhs.uk/alpha
Further information – 02476 967697

University Hospital Birmingham

www.uhb.nhs.uk/alpha
Further information – 0121 371 3885

Published: 18/09/2015

CSL Behring Receives Marketing Authorization for Respreeza® in Europe

Respreeza® is a maintenance treatment for severe Alpha-1 Antitrypsin Deficiency patients and has been shown to slow the progression of emphysema

CSL Behring announced today that the European Commission (EC) has granted marketing authorization in all European Union (EU) member states for Respreeza® to treat patients with Alpha-1 antitrypsin deficiency (AATD). Respreeza®, a highly purified Alpha-1 protein derived from human plasma, is the only Alpha-1 proteinase inhibitor that has been proven in a prospective double blind, placebo controlled trial (the RAPID study) to significantly reduce the loss of lung tissue, slowing the progression of emphysema due to AATD. AATD is a hereditary condition marked by a lack of the Alpha-1 antitrypsin protein, whose main function is to protect the lungs from inflammation.

“AATD is a potentially debilitating disease and many affected individuals suffer from serious lung disease,” said Professor Helmut Teschler, MD, Director of the West German Lung Centre at the University of Essen. “With the approval of Respreeza®, healthcare professionals can now provide patients with severe AATD in Europe with a next generation Alpha1-proteinase inhibitor (A1-PI) that provided additional evidence that this augmentation therapy can slow the accelerated loss of lung tissue.”

Frank Willersinn, M.D., Alpha-1 Global Steering Committee Chair and patient representative in Europe added, “We are so glad that Respreeza® has been approved by the European Medicines Agency. We commend CSL Behring for their long-lasting commitment to the Alpha-1 community, now bringing their established Alpha 1-antitrypsin product to Europe, allowing it to be a cornerstone for treatment of AATD patients in the near future.”

CSL Behring has marketed A1-PI for 12 years as Zemaira® in the United States, where it is indicated for chronic augmentation and maintenance therapy in adults with A1-PI deficiency and clinical evidence of emphysema. In US, Zemaira® is contraindicated in patients with a history of severe systemic reaction to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira® is also contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA.

About Respreeza®

In EU, Respreeza® is indicated for maintenance treatment, and to slow the progression of emphysema in adults with documented severe A1-PI deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of A1-PI deficiency. Respreeza® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and IgA deficient patients with known antibodies against IgA, due to the risk of severe hypersensitivity and anaphylactic reactions.

About the RAPID Study

The RAPID study (Randomized, Placebo-controlled Trial of Augmentation Therapy in Alpha-1 Proteinase Inhibitor Deficiency) enrolled 180 severely deficient alpha-1 patients in the U.S. and Europe who were treated for 2 years with Respreeza® or Placebo. The study, published in Lancet in June 2015, showed a significant reduction in the rate of lung tissue loss as measured by CT scan lung density. In those patients who continued into the extension study, where all subjects received Respreeza®, the benefit was maintained for another 2 years.

Full Story: CSL Behring 25/08/2015

Step Closer to First UK Drug License Augmentation Therapy

One step closer to the first UK drug license for augmentation therapy for patients with severe alpha-1 antitrypsin deficiency

CSL Behring has announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a market authorisation to CSL’s alpha-1 antitrypsin augmentation therapy product Respreeza®.

Receiving a positive CHMP opinion (See EMA Website) marks an important milestone in the process of Respreeza® obtaining a market authorisation (= drug license) in all EU Member States, including the UK. The CHMP positive opinion will be transmitted to the European Commission (EC) to start the EC decision-making process on granting a centralised European drug license for Respreeza®, which we hope to be concluded later this year.

Lutz Bonacker, Senior Vice President & General Manager Commercial Operations, Europe, CSL Behring said: “CSL Behring continues to make strides towards fulfilling our promise to improve the lives of our patients. This positive opinion from CHMP brings us closer to providing Respreeza® as a new treatment option to the AATD community in Europe.”

However, once a drug license is granted by the EC, access to Respreeza® to UK patients will be subject to reimbursement of the drug by the NHS. As use of Respreeza® will be indicated in adults with documented severe alpha-1 antitrypsin deficiency and evidence of progressive lung disease as evaluated by a healthcare professional experienced in the treatment of Alpha-1, it is important that patients gain access to the care provided by a physician with sufficient experience in the field of Alpha-1, e.g. at the recently established West Midlands Alpha-1 Services


Published: 29/06/2015

Trial Results Alpha-1 Augmentation Therapy

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy.

The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial in The Lancet, one of the world’s oldest and most prestigious medical journals.

The Lancet article was posted online this week.

When the results were first announced at the international conference of the American Thoracic Society (ATS) in 2013, lead author Kenneth Chapman, MD, director of the Asthma and Airway Centre of the University Health Network in Toronto, Canada, called the trial “the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 Antitrypsin Deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease.”

The Alpha-1 Foundation hailed the trial results and The Lancet publication. “We congratulate CSL on this landmark clinical trial, which provides the strongest evidence yet that augmentation therapy preserves the lung tissue of individuals with Alpha-1-related lung disease,” said John Walsh, Foundation president and CEO. “We hope these results will support Alpha-1 communities around the world in their efforts to win access to therapy.”

Walsh said, “The Foundation has communicated its support for acceptance of the RAPID data as proof of efficacy of augmentation therapy to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (the European equivalent of the FDA), and has continued a dialogue with both agencies to urge acceptance of these findings.”

CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period, followed by a two year of open-label extension study in which all subjects were offered augmentation therapy. “We applaud CSL for its commitment of time and effort to conduct this multinational, multi-year study, and we’re delighted that The Lancet has published the RAPID Trial results,” said Walsh. 

The Lancet article says that an interim analysis of data from the two-year extension trial suggest that early treatment with augmentation therapy shows persistent efficacy in patients with Alpha-1 and emphysema. In addition, when patients who had been receiving a placebo in the original two-year trial switched to treatment with augmentation therapy, their lung density decline (which was more rapid than the treated group in the main study) slowed to the same rate as the treatment group. “These findings should encourage early introduction of augmentation therapy [in patients with emphysema due to Alpha-1] and should stimulate further research into optimum dosing,” says the Lancet article.

Robert Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet, was a co-author of the Lancet article.

The RAPID Trial is the first well-powered randomized, placebo-controlled trial to use CT scan lung density as the primary outcome measure. CT scans are currently considered the most sensitive measure of emphysema detection. The trial was conducted at 28 sites in the United States, Europe, Canada, Australia and Russia.

The multi-center, multi-national trial randomized patients with homozygous Alpha-1 (ZZ) to receive either alpha-1 antitrypsin augmentation therapy intravenously at 60 mg/kg weekly or a placebo over two years. CT scan lung density was measured at baseline, three months, one and two years. Secondary endpoints included spirometry, changes in exercise capacity and the rate of pulmonary exacerbations over two years.

The annual rate of lung density loss was significantly less in augmentation-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one-sided). Secondary outcome variables and adverse events were not significantly different between groups, according to the article. There was one death in the augmentation therapy group and three in the placebo group.

Attached is the full article published in The Lancet, with an accompanying editorial by Ron Crystal, MD, Department of Genetic Medicine, Weill Cornell Medical College.

Source: Alpha-1 Foundation 28/05/2015

 

New Specialist NHS Clinics for Alpha-1

New NHS Funded Multi Disciplinary Service for Alpha-1 Patients

Specialist NHS clinics for patients with alpha 1-antitrypsin deficiency will be running in the West Midlands from the end of May 2015 to cover all aspects of alpha 1. The clinics will be run at University Hospital Coventry by Dr David Parr and at University Hospital Birmingham by Dr David Parr and Dr Alice Turner. The services at both hospitals will be run in conjunction with hepatologists (liver doctors) and dermatologists (skin doctors) and there will be close links with the transplant services and the Genetics Department at University Hospital Birmingham.

Bookings for the clinic in Coventry can be made from the end of May, and an update will follow on a start date for clinics in Birmingham. Patients wishing to be seen in either of the clinics should see their GP to arrange a referral through ‘Choose and Book’, which will enable them to book into the alpha 1 clinic of their choice. Further information can be obtained by contacting Wendi Wallace in Coventry (02476 967697) or Rebecca Bray in Birmingham (0121 3713885). The following links can also be used to access information about the two hospitals and each clinic;

Coventry – www.uhcw.nhs.uk/alpha

Birmingham – www.uhb.nhs.uk/alpha

Please Note: Birmingham web link is not live yet

The ADAPT research programme will continue to be based in Birmingham, and patients attending either NHS clinic who would also like to participate in alpha 1 research will still have the opportunity to do so.


Published: 28/04/2015

Clinical Trials Begin to Treat Alpha-1 Liver Disease

TAP collaborator Arrowhead begins clinical trials on ARC-AAT to treat Alpha-1 liver disease. A groundbreaking trial of a potential treatment for Alpha-1-related liver disease has begun in Australia.Research poster design

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, on Monday announced it has started dosing in a Phase 1 clinical trial of ARC-AAT, the company’s candidate for treating Alpha-1-related liver disease.

Arrowhead partnered with The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, in June 2014 to develop treatment for Alpha-1 liver disease. Under the agreement, TAP will partially fund the development of ARC-AAT. In addition to the funding, TAP is making its scientific advisors available to Arrowhead, assisting with patient recruitment for clinical trials thanks to the Alpha-1 Foundation Patient Research Registry, and engaging in other collaborative efforts that support ARC-AAT development.



Source: Alpha-1 Foundation 23/02/2015

Cabinet Health Secretary commits to improving care

In a landmark seminar at the Scottish Parliament last week, the Alpha-1 Alliance moved one step closer to achieving its goal of improving health services for patients of the condition in Scotland – with a personal commitment to improve care for the rare disease from Health Secretary Alex Neil MSP.

The event, which was chaired by Dr Aileen McLeod MSP, served as a platform to discuss the Alliance’s policy report on the unmet medical need of Alpha-1 patients in Scotland – which was informed by the findings of the Alliance’s 2013 survey of Scottish Alpha-1 patients, relatives and carers.

Members of the Alpha-1 patient community, specialists clinicians, government officials and politicians came together to talk about what steps can practically be taken to establish a nationally commissioned specialist service for Alpha-1. The Alliance was pleased to welcome a number of MSPs to the event, including Conservative spokesman for Health and Community Care Nanette Milne, Linda Fabiani, Iain Gray, Christian Allard and Minister for Children and Young People Aileen Campbell.

Karen North, an Alpha-1 patient and Chair of the Alliance, and Fay Whittaker, an Alpha-1 patient and member of the Alpha-1 UK Support Group, both spoke of their experiences with the condition and about the need for better care for Scottish Alphas.

Professor MacNee, Chair of the Alliance Scotland and Professor of Respiratory and Environmental Medicine at the University of Edinburgh, provided further evidence of the high unmet medical need experienced by Scottish Alpha-1 sufferers in his presentation on the 2013 survey’s findings –confirming the pressing need to establish a national specialist service.

Cabinet Secretary for Health and Wellbeing Alex Neil MSP made a firm commitment to improve services for Scottish Alpha-1 patients, pledging to implement a ‘step change’ in Alpha-1 care. Mr Neil also indicated his intention to initiate a dialogue with the health ministers of the other UK nations to accelerate access to treatment.

“This is a really significant and encouraging commitment to receive from a government Minister” said Chair of the Alliance Karen North “the Alliance will now be doing everything it can to ensure that these changes are impended as quickly as possible”.

Following an overview on the context of specialised commissioning presented by Elizabeth Porterfield, a government official at the Quality Unit of the Scottish Government Health and Social Care Directorates, the event ended with a Q&A session between the audience and panel speakers.

The Alliance will now begin to formally engage with NHS Scotland regarding the establishment of a specialist service for Alpha-1.

Source: Alpha-1 Alliance 24/11/2014